REFERENCES
1. Lefevre PG. Evidence of active transfer of certain non-electrolytes across the human red cell membrane. J Gen Physiol. 1948;31:505-27.
2. Baldwin JM, Gorga JC, Lienhard GE. The monosaccharide transporter of the human erythrocyte. Transport activity upon reconstitution. J Biol Chem. 1981;256:3685-9.
3. Carbó R, Rodríguez E. Relevance of sugar transport across the cell membrane. Int J Mol Sci. 2023;24:6085.
4. Chadt A, Al-Hasani H. Glucose transporters in adipose tissue, liver, and skeletal muscle in metabolic health and disease. Pflugers Arch - Eur J Physiol. 2020;472:1273-98.
6. Lizák B, Szarka A, Kim Y, et al. Glucose transport and transporters in the endomembranes. Int J Mol Sci. 2019;20:5898.
7. Ji J, Yang L, Fang Z, et al. Plant SWEET family of sugar transporters: structure, evolution and biological functions. Biomolecules. 2022;12:205.
8. Thomas MC, Neuen BL, Twigg SM, Cooper ME, Badve SV. SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review. Endocr Connect. 2023;12:e230005.
9. Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. Sci Rep. 2023;13:15922.
10. Theodorakopoulou MP, Alexandrou M, Tsitouridis A, et al. Effects of sodium-glucose co-transporter 2 inhibitors on heart failure events in chronic kidney disease: a systematic review and meta-analysis. Eur Heart J-Card Pha. 2024;10:329-41.
11. Santos GL, Dos Santos CF, Rocha GR, et al. Beyond glycemic control: roles for sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in diabetic kidney disease. World J Diabetes. 2025;16:104706.
12. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28.
13. Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Mol Aspects Med. 2013;34:121-38.
14. Nevola R, Villani A, Imbriani S, et al. Sodium-glucose co-transporters family: current evidence, clinical applications and perspectives. Front Biosci (Landmark Ed). 2023;28:103.
15. Joost H, Bell GI, Best JD, et al. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol-Endoc M. 2002;282:E974-6.
16. Scheepers A, Joost H, Schurmann A. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function. J Parenter Enteral Nutr. 2004;28:364-71.
17. Thorens B, Mueckler M. Glucose transporters in the 21st Century. Am J Physiol-Endoc M. 2010;298:E141-5.
18. Uldry M, Ibberson M, Horisberger JD, Chatton JY, Riederer BM, Thorens B. Identification of a mammalian H+-myo-inositol symporter expressed predominantly in the brain. EMBO J. 2001;20:4467-77.
19. Du J, Shen M, Chen J, et al. The impact of solute carrier proteins on disrupting substance regulation in metabolic disorders: insights and clinical applications. Front Pharmacol. 2025;15:1510080.
20. Lefevre PG, Marshall JK. The atachment of phloretin and analogues to human erythrocytes in connection with inhibition of sugar transport. J Biol Chem. 1959;234:3022-6.
21. Estensen RD, Plagemann PGW. Cytochalasin B: Inhibition of glucose and glucosamine transport. Proc Natl Acad Sci USA. 1972;69:1430-4.
22. Wang N, Zhang S, Yuan Y, et al. Molecular basis for inhibiting human glucose transporters by exofacial inhibitors. Nat Commun. 2022;13:2632.
23. Thorens B, Sarkar HK, Kaback H, Lodish HF. Cloning and functional expression in bacteria of a novel glucose transporter present in liver, intestine, kidney, and β-pancreatic islet cells. Cell. 1988;55:281-90.
24. Wang J, Ye C, Chen C, et al. Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget. 2017;8:16875-86.
25. Veys K, Fan Z, Ghobrial M, et al. Role of the GLUT1 Glucose transporter in postnatal CNS angiogenesis and blood-brain barrier integrity. Circ Res. 2020;127:466-82.
26. Matar R, Tang D, Mccall S, De Silva R. Glucose transporter type 1 deficiency syndrome and paroxysmal exercise-induced dyskinesia. Pract Neurol. 2025;25:75-7.
27. Li H, Guglielmetti C, Sei YJ, et al. Neurons require glucose uptake and glycolysis in vivo. Cell Reports. 2023;42:112335.
28. Szablewski L. Glucose transporters as markers of diagnosis and prognosis in cancer diseases. Oncol Rev. 2022;16.
29. Huang Y, Lin D, Taniguchi CM. Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? Sci. China Life Sci. 2017;60:1114-24.
30. Basheeruddin M, Qausain S. Hypoxia-inducible factor 1-alpha (HIF-1α) and cancer: mechanisms of tumor hypoxia and therapeutic targeting. Cureus. 2024;16:e70700.
31. Zha X, Hu Z, Ji S, et al. NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth. Cancer Lett. 2015;359:97-106.
32. Yu L, Chen X, Sun X, Wang L, Chen S. The glycolytic switch in tumors: how many players are involved? J. Cancer. 2017;8:3430-40.
33. Yu L, Wu M, Zhu G, Xu Y. Emerging roles of the tumor suppressor p53 in metabolism. Front Cell Dev Biol. 2022;9:762742.
34. Pliszka M, Szablewski L. Glucose transporters as a target for anticancer therapy. Cancers. 2021;13:4184.
35. Koepsell H. Glucose transporters in brain in health and disease. Pflugers Arch - Eur J Physiol. 2020;472:1299-343.
36. Fakorede S, Sodiq TA, Ajagbe AO, et al. Interplay of Glut1 alteration and Alzheimer’s disease: a narrative review on glucose transport and energy metabolism. J Alzheimers Dis. 2025;108:470-86.
37. Daida T, Shin B, Cepeda C, Devaskar SU. Neurodevelopment is dependent on maternal diet: placenta and brain glucose transporters GLUT1 and GLUT3. Nutrients. 2024;16:2363.
38. Toyoda Y, Shigesawa R, Merriman TR, Matsuo H, Takada T. GLUT2/SLC2A2 is a bi-directional urate transporter. J Biol Chem. 2025;301:108485.
39. Uldry M, Ibberson M, Hosokawa M, Thorens B. GLUT2 is a high affinity glucosamine transporter. FEBS Lett. 2002;524:199-203.
40. Sun B, Chen H, Xue J, Li P, Fu X. The role of GLUT2 in glucose metabolism in multiple organs and tissues. Mol Biol Rep. 2023;50:6963-74.
41. Guillam M, Burcelin R, Thorens B. Normal hepatic glucose production in the absence of GLUT2 reveals an alternative pathway for glucose release from hepatocytes. Proc Natl Acad Sci USA. 1998;95:12317-21.
42. Troncoso MF, Elola MT, Blidner AG, Sarrias L, Espelt MV, Rabinovich GA. The universe of galectin-binding partners and their functions in health and disease. J Biol Chem. 2023;299:105400.
43. Hall E, Jönsson J, Ofori JK, et al. Glucolipotoxicity alters insulin secretion via epigenetic changes in human islets. Diabetes. 2019;68:1965-74.
44. Ohtsubo K, Takamatsu S, Minowa MT, Yoshida A, Takeuchi M, Marth JD. Dietary and genetic control of glucose transporter 2 glycosylation promotes insulin secretion in suppressing diabetes. Cell. 2005;123:1307-21.
45. Ng NHJ, Ghosh S, Bok CM, et al. HNF4A and HNF1A exhibit tissue specific target gene regulation in pancreatic beta cells and hepatocytes. Nat Commun. 2024;15:4288.
46. Afshar N, Safaei S, Nickerson DP, Hunter PJ, Suresh V. Computational Modelling of glucose uptake by SGLT1 and apical GLUT2 in the enterocyte. Front Physiol. 2021;12:699152.
47. Vallon V, Nakagawa T. Renal tubular handling of glucose and fructose in health and disease. In: Prakash YS, Editors. Comprehensive Physiology. Wiley; 2021. pp. 2995-3044.
48. Morgan EL, Mace OJ, Affleck J, Kellett GL. Apical GLUT2 and Cav1.3: regulation of rat intestinal glucose and calcium absorption. J Physiol. 2007;580:593-604.
49. Morgan E, Mace O, Helliwell P, Affleck J, Kellett G. A role for Cav1.3 in rat intestinal calcium absorption. Biochem Biophys Res Commun. 2003;312:487-93.
50. Pfaff IL, Vallon V. Protein Kinase C Beta isoenzymes in diabetic kidneys and their relation to nephroprotective actions of the ace inhibitor lisinopril. Kidney Blood Press Res. 2002;25:329-40.
51. Goestemeyer AK, Marks J, Srai SK, Debnam ES, Unwin RJ. GLUT2 protein at the rat proximal tubule brush border membrane correlates with protein kinase C (PKC)-βl and plasma glucose concentration. Diabetologia. 2007;50:2209-17.
52. Gouyon F, Caillaud L, Carrière V, et al. Simple-sugar meals target GLUT2 at enterocyte apical membranes to improve sugar absorption: a study in GLUT2-null mice. J Physiol. 2003;552:823-32.
53. Tobin V, Le Gall M, Fioramonti X, et al. Insulin internalizes GLUT2 in the enterocytes of healthy but not insulin-resistant mice. Diabetes. 2008;57:555-62.
54. Ferraris RP. Dietary and developmental regulation of intestinal sugar transport. Biochem J. 2001;360:265.
55. Shen Z, Hou Y, Zhao G, et al. Physiological functions of glucose transporter-2: from cell physiology to links with diabetes mellitus. Heliyon. 2024;10:e25459.
56. Gromova LV, Fetissov SO, Gruzdkov AA. Mechanisms of glucose absorption in the small intestine in health and metabolic diseases and their role in appetite regulation. Nutrients. 2021;13:2474.
57. Fanconi G, Bickel H. Chronic aminoaciduria (amino acid diabetes or nephrotic-glucosuric dwarfism) in glycogen storage and cystine disease. Helv Paediatr Acta. 1949;4:359-96.
58. Santer R, Schneppenheim R, Dombrowski A, Götze H, Steinmann B, Schaub J. Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet. 1997;17:324-6.
59. Sharari S, Abou-alloul M, Hussain K, Ahmad Khan F. Fanconi-Bickel syndrome: a review of the mechanisms that lead to dysglycaemia. Int J Mol Sci. 2020;21:6286.
60. Drobiova H, Alhamar G, Ahmad R, Al-Mulla F, Al Madhoun A. GLUT4 trafficking and storage vesicles: molecular architecture, regulatory networks, and their disruption in insulin resistance. Int J Mol Sci. 2025;26:7568.
61. Van Gerwen J, Shun-Shion AS, Fazakerley DJ. Insulin signalling and GLUT4 trafficking in insulin resistance. Biochem Soc Trans. 2023;51:1057-69.
64. Chang Y, Chan M, Yang Y, Li C, Hsiao M. Glucose transporter 4: Insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression. Cancer Lett. 2023;563:216179.
65. Holman GD. Structure, function and regulation of mammalian glucose transporters of the SLC2 family. Pflugers Arch - Eur J Physiol. 2020;472:1155-75.
66. Zisman A, Peroni OD, Abel ED, et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med. 2000;6:924-8.
67. Abel ED, Peroni O, Kim JK, et al. Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver. Nature. 2001;409:729-33.
68. Mcgee SL, Hargreaves M. Exercise performance and health: role of GLUT4. Free Radic Biol Med. 2024;224:479-83.
69. Mizuno TM, Lew PS, Jhanji G. Regulation of the fructose transporter gene Slc2a5 expression by glucose in cultured microglial cells. Int J Mol Sci. 2021;22:12668.
70. Zwarts I, Van Zutphen T, Kruit JK, et al. Identification of the fructose transporter GLUT5 (SLC2A5) as a novel target of nuclear receptor LXR. Sci Rep. 2019;9:9299.
71. Spellman MJ, Assaf T, Nangia S, Fernandez J, Nicholson KC, Shepard BD. Handling the sugar rush: the role of the renal proximal tubule. Am J Physiol Renal Physiol. 2024;327:F1013-25.
72. Patel C, Douard V, Yu S, Gao N, Ferraris RP. Transport, metabolism, and endosomal trafficking-dependent regulation of intestinal fructose absorption. FASEB j. 2015;29:4046-58.
73. Song A, Mao Y, Wei H. GLUT5: structure, functions, diseases and potential applications. Acta Biochim Biophys Sin. 2023;55:1519-38.
74. Demirel MA, Şumlu E, Özercan İH. Impact of high-fructose diet and metformin on histomorphological and molecular parameters of reproductive organs and vaginal microbiota of female rat. Sci Rep. 2024;14:27463.
75. Socha-Banasiak A, Sakowicz A, Gaj Z, Kolejwa M, Gach A, Czkwianianc E. Intestinal fructose transporters GLUT5 and GLUT2 in children and adolescents with obesity and metabolic disorders. Adv Med Sci. 2024;69:349-55.
76. Li Z, Fan X, Gao F, et al. Fructose metabolism and its roles in metabolic diseases, inflammatory diseases, and cancer. Mol Biomed. 2025;6:43.
77. Simões CD, Sousa AS, Fernandes S, Sarmento A. Fructose malabsorption, gut microbiota and clinical consequences: a narrative review of the current evidence. Life. 2025;15:1720.
78. Staubach P, Koch AK, Langhorst J, Schreiber S, Röcken C, Helwig U. Expression of the fructose transporter GLUT5 in patients with fructose malabsorption. Z Gastroenterol. 2021;59:531-9.
79. Barone S, Fussell SL, Singh AK, et al. Slc2a5 (Glut5) is essential for the absorption of fructose in the intestine and generation of fructose-induced hypertension. J Biol Chem. 2009;284:5056-66.
80. Zhou P, Chang W, Gong D, et al. High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate. Cell Metab. 2023;35:1961-1975.e6.
81. Segerstolpe Å, Palasantza A, Eliasson P, et al. Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes. Cell Metab. 2016;24:593-607.
82. Dyer J, Wood IS, Palejwala A, Ellis A, Shirazi-Beechey SP. Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastr L. 2002;282:G241-8.
83. Corpe C, Sreenan S, Burant C. Effects of type-2 diabetes and troglitazone on the expression patterns of small intestinal sugar transporters and PPAR-gamma in the Zucker diabetic fatty rat. Digestion. 2001;63:116-23.
84. Litherland GJ, Hajduch E, Gould GW, Hundal HS. Fructose transport and metabolism in adipose tissue of Zucker rats: diminished GLUT5 activity during obesity and insulin resistance. Mol Cell Biochem. 2004;261:23-33.
85. Manolescu A, Salas-burgos AM, Fischbarg J, Cheeseman CI. Identification of a hydrophobic residue as a key determinant of fructose transport by the facilitative hexose transporter SLC2A7 (GLUT7). J Biol Chem. 2005;280:42978-83.
86. Manolescu AR, Augustin R, Moley K, Cheeseman C. A highly conserved hydrophobic motif in the exofacial vestibule of fructose transporting SLC2A proteins acts as a critical determinant of their substrate selectivity. Mol Membr Biol. 2009;24:455-63.
87. Ebert K, Ludwig M, Geillinger KE, et al. Reassessment of GLUT7 and GLUT9 as putative fructose and glucose transporters. J Membrane Biol. 2017;250:171-82.
88. Ebert K, Ewers M, Bisha I, et al. Identification of essential amino acids for glucose transporter 5 (GLUT5)-mediated fructose transport. J Biol Chem. 2018;293:2115-24.
89. Matsushita D, Toyoda Y, Lee Y, et al. Structural basis of urate transport by glucose transporter 9. Cell Reports. 2025;44:115514.
90. Pommereau A, Sassone F, Poli A, et al. The development of a novel high-throughput membrane potential assay and a solid-supported membrane (SSM)-based electrophysiological assay to study the pharmacological inhibition of GLUT9/SLC2A9 isoforms in a drug discovery program. SLAS Discovery. 2024;29:100193.
91. Kim SH, Shin J, Son H, Kang D. Role of urate transporters in the kidneys and intestine in uric acid homeostasis. Kidney Res Clin Pract. 2026;45:296-313.
92. Khandelwal NK, Gupta M, Kumar P, Balasubramani SG, Echeverria I, Stroud RM. Structural basis of disease mutation and substrate recognition by the human SLC2A9 transporter. Proc. Natl. Acad. Sci. U.S.A. 2025;122:e2418282122.
93. Meng Q, Yue J, Shang M, et al. Correlation of GLUT9 polymorphisms with gout risk. Medicine (Baltimore). 2015;94:e1742.
94. Scheepers A, Schmidt S, Manolescu A, et al. Characterization of the humanSLC2A11(GLUT11) gene: alternative promoter usage, function, expression, and subcellular distribution of three isoforms, and lack of mouse orthologue. Mol Membr Biol. 2009;22:339-51.
95. Ferreira RS, Pons J, Labesse G. Insights into substrate and inhibitor selectivity among human GLUT transporters through comparative modeling and molecular docking. ACS Omega. 2019;4:4748-60.
96. Burgos M, Gil-Iturbe E, Idoate-Bayón A, Castilla-Madrigal R, Moreno-Aliaga MJ, Lostao MP. The glucose transporter GLUT12, a new actor in obesity and cancer. J Physiol Biochem. 2024;81:391-401.
97. Maedera S, Mizuno T, Ishiguro H, Ito T, Soga T, Kusuhara H. GLUT6 is a lysosomal transporter that is regulated by inflammatory stimuli and modulates glycolysis in macrophages. FEBS Lett. 2018;593:195-208.
98. Byrne FL, Olzomer EM, Brink R, Hoehn KL. Knockout of glucose transporter GLUT6 has minimal effects on whole body metabolic physiology in mice. Am J Physiol-Endoc M. 2018;315:E286-93.
99. Ismail A, Tanasova M. Importance of GLUT transporters in disease diagnosis and treatment. Int J Mol Sci. 2022;23:8698.
100. Xi H, Zhang Z, Ji R, et al. Expression of glucose transporter 8 (GLUT8) in spermatogenesis of adult boar testes. Acta Histochem. 2017;119:632-7.
101. Novelle MG, Bravo SB, Deshons M, et al. Impact of liver-specific GLUT8 silencing on fructose-induced inflammation and omega oxidation. iScience. 2021;24:102071.
102. Debosch BJ, Chen Z, Saben JL, Finck BN, Moley KH. Glucose transporter 8 (GLUT8) mediates fructose-induced de novo lipogenesis and macrosteatosis. J Biol Chem. 2014;289:10989-98.
103. Jiang C, Jen W, Tsao C, Chang L, Chen C, Lee Y. Glucose transporter 10 modulates adipogenesis via an ascorbic acid-mediated pathway to protect mice against diet-induced metabolic dysregulation. PLoS Genet. 2020;16:e1008823.
104. Lee Y, Huang H, Chang C, Cheng C, Chen Y. Mitochondrial GLUT10 facilitates dehydroascorbic acid import and protects cells against oxidative stress: mechanistic insight into arterial tortuosity syndrome. Hum Mol Genet. 2010;19:3721-33.
105. Ekhator C, Devi M, Barker C, et al. Arterial tortuosity syndrome: unraveling a rare vascular disorder. Cureus. 2023;15:e44906.
106. Coucke PJ, Willaert A, Wessels MW, et al. Mutations in the facilitative glucose transporter GLUT10 alter angiogenesis and cause arterial tortuosity syndrome. Nat Genet. 2006;38:452-7.
107. Gil-Iturbe E, Arbones-Mainar JM, Moreno-Aliaga MJ, Lostao MP. GLUT12 and adipose tissue: expression, regulation and its relation with obesity in mice. Acta Physiol. 2019;226:e13283.
108. Gil-Iturbe E, Castilla-Madrigal R, Barrenetxe J, Villaro AC, Lostao MP. GLUT12 expression and regulation in murine small intestine and human Caco-2 cells. J Cell Physiol. 2018;234:4396-408.
109. Stuart CA, Howell MEA, Zhang Y, Yin D. Insulin-stimulated translocation of glucose transporter (GLUT) 12 parallels that of GLUT4 in normal muscle. J Clin Endocr Metab. 2009;94:3535-42.
110. Rogers S, Macheda ML, Docherty SE, et al. Identification of a novel glucose transporter-like protein - GLUT-12. Am J Physiol-Endoc M. 2002;282:E733-8.
111. Purcell SH, Aerni-Flessner LB, Willcockson AR, Diggs-Andrews KA, Fisher SJ, Moley KH. Improved insulin sensitivity by GLUT12 overexpression in mice. Diabetes. 2011;60:1478-82.
112. Shi Y, Zhang Y, Ran F, et al. Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect. Cancer Lett. 2020;495:53-65.
113. White MA, Tsouko E, Lin C, et al. GLUT12 promotes prostate cancer cell growth and is regulated by androgens and CaMKK2 signaling. Endocr-Relat Cancer. 2018;25:453-69.
114. Wilson-O’Brien AL, Patron N, Rogers S. Evolutionary ancestry and novel functions of the mammalian glucose transporter (GLUT) family. BMC Evol Biol. 2010;10:152.
115. Gyimesi G, Pujol-Giménez J, Kanai Y, Hediger MA. Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application. Pflugers Arch - Eur J Physiol. 2020;472:1177-206.
116. Turk E, Wright E. Membrane topology motifs in the SGLT cotransporter family. J Membrane Biol. 2014;159:1-20.
117. Levy O, De La Vieja A, Ginter CS, Riedel C, Dai G, Carrasco N. N-linked glycosylation of the thyroid Na+/I- symporter (NIS). J Biol Chem. 1998;273:22657-63.
118. Hediger MA, Romero MF, Peng J, Rolfs A, Takanaga H, Bruford EA. The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflug Arch Eur J Phy. 2004;447:465-8.
120. Schultz SG, Curran PF. Coupled transport of sodium and organic solutes. Physiol Rev. 1970;50:637-718.
121. Elferink H, Bruekers JPJ, Veeneman GH, Boltje TJ. A comprehensive overview of substrate specificity of glycoside hydrolases and transporters in the small intestine: “a gut feeling”. Cell Mol Life Sci. 2020;77:4799-826.
122. Chowdhury CR, Havlik J. Beyond sweetness: a review of the health and safety of acesulfame-K. Food Chem. 2026;499:147290.
123. Posta E, Fekete I, Gyarmati E, Stündl L, Zold E, Barta Z. The effects of artificial sweeteners on intestinal nutrient-sensing receptors: Dr. Jekyll or Mr. Hyde? Life. 2023;14:10.
124. Pang MD, Goossens GH, Blaak EE. The impact of artificial sweeteners on body weight control and glucose homeostasis. Front Nutr. 2021;7:598340.
125. Kreuch D, Keating DJ, Wu T, Horowitz M, Rayner CK, Young RL. Gut mechanisms linking intestinal sweet sensing to glycemic control. Front Endocrinol. 2018;9:741.
126. Iizuka K. Is the use of artificial sweeteners beneficial for patients with diabetes mellitus? The advantages and disadvantages of artificial sweeteners. Nutrients. 2022;14:4446.
127. Takata K, Kasahara T, Kasahara M, Ezaki O, Hirano H. Immunohistochemical localization of Na+-dependent glucose transporter in rat jejunum. Cell Tissue Res. 1992;267:3-9.
128. Vrhovac I, Balen Eror D, Klessen D, et al. Localizations of Na+-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch - Eur J Physiol. 2014;467:1881-98.
129. Hediger MA, Coady MJ, Ikeda TS, Wright EM. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature. 1987;330:379-81.
130. Holst JJ, Albrechtsen NJW, Rosenkilde MM, Deacon CF. Physiology of the incretin hormones, GIP and GLP-1 - regulation of release and posttranslational modifications. Compr Physiol. 2019;9:1339-81.
131. Yamanouchi D. The roles of incretin hormones GIP and GLP-1 in metabolic and cardiovascular health: a comprehensive review. Int J Mol Sci. 2025;27:27.
132. Qiao Y, Zhou F, Mao T, Gao L. Revitalizing GIP: therapeutic potential in metabolic and neurodegenerative disorders. Diabetes Metab Syndr Obes. 2026;19:559587.
133. Nauck MA, Tuttle KR, Tschöp MH, Blüher M. GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. The Lancet. 2026;407:892-908.
135. Hong S, Choi KM. Gut hormones and appetite regulation. Curr Opin Endocrinol Diabetes Obes. 2024;31:115-21.
136. Duca FA, Waise TMZ, Peppler WT, Lam TKT. The metabolic impact of small intestinal nutrient sensing. Nat Commun. 2021;12:903.
137. Miyamoto K, Hase K, Takagi T, et al. Differential responses of intestinal glucose transporter mRNA transcripts to levels of dietary sugars. Biochem J. 1993;295:211-5.
138. Chintalapati C, Keller T, Mueller TD, et al. Protein RS1 (RSC1A1) downregulates the exocytotic pathway of glucose transporter SGLT1 at low intracellular glucose via inhibition of ornithine decarboxylase. Mol Pharmacol. 2016;90:508-21.
139. Smith K, Karimian Azari E, Lamoia TE, et al. T1R2 receptor-mediated glucose sensing in the upper intestine potentiates glucose absorption through activation of local regulatory pathways. Mol Metab. 2018;17:98-111.
140. Cheeseman CI. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Physiol - Regul Integr Comp Physiol. 1997;273:R1965-71.
141. Moran AW, Al-Rammahi MA, Batchelor DJ, Bravo DM, Shirazi-Beechey SP. Glucagon-like peptide-2 and the enteric nervous system are components of cell-cell communication pathway regulating intestinal Na+/glucose co-transport. Front Nutr. 2018;5:101.
142. Margolskee RF, Dyer J, Kokrashvili Z, et al. T1R3 and gustducin in gut sense sugars to regulate expression of Na+-glucose cotransporter 1. Proc. Natl. Acad. Sci. U.S.A. 2007;104:15075-80.
143. Ferraris RP, Diamond JM. Crypt/villus site of substrate-dependent regulation of mouse intestinal glucose transporters. Proc. Natl. Acad. Sci. U.S.A. 1993;90:5868-72.
144. Gorboulev V, Schürmann A, Vallon V, et al. Na(+)-d-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes. 2012;61:187-96.
145. Alsalim W, Lindgren O, Ahrén B. Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 secretion in humans: characteristics and regulation. J Diabetes Invest. 2022;14:354-61.
146. Poulsen SB, Fenton RA, Rieg T. Sodium-glucose cotransport. Curr Opin Nephrol Hypertens. 2015;24:463-9.
147. Lostao M, Urdaneta E, Martı́nez-Ansó E, Barber A, Martı́nez J. Presence of leptin receptors in rat small intestine and leptin effect on sugar absorption. FEBS Lett. 1998;423:302-6.
148. Kelesidis T, Kelesidis I, Chou S, Mantzoros CS. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 2010;152:93-100.
150. Tavernier A, Cavin JB, Le Gall M, et al. Intestinal deletion of leptin signaling alters activity of nutrient transporters and delayed the onset of obesity in mice. FASEB J. 2014;28:4100-10.
151. Ye Y, Zhang X, Yao J, Lei X. Advances in intestinal glucose absorption regulation for ruminant energy efficiency improvement. Animals. 2026;16:659.
152. Wellington VNA, Singh S. The adipose tissue-derived secretome (ADS) in obesity uniquely regulates the Na-glucose transporter SGLT1 in intestinal epithelial cells. Cells. 2025;14:1241.
153. Miyamoto K, Hase K, Taketani Y, et al. Diabetes and glucose transporter gene expression in rat small intestine. Biochem Biophys Res Commun. 1991;181:1110-7.
154. Fujita Y, Kojima H, Hidaka H, Fujimiya M, Kashiwagi A, Kikkawa R. Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty Rats. Diabetologia. 1998;41:1459-66.
155. Yamamoto K, Harada N, Yasuda T, et al. Intestinal morphology and glucose transporter gene expression under a chronic intake of high sucrose. Nutrients. 2024;16:196.
156. Biter LU, ‘t Hart JW, Noordman BJ, et al. Long-term effect of sleeve gastrectomy vs Roux-en-Y gastric bypass in people living with severe obesity: a phase III multicentre randomised controlled trial (SleeveBypass). Lancet Reg Health Eur. 2024;38:100836.
157. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376:641-51.
158. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. The Lancet. 2015;386:964-73.
159. Mohamed AM, Aljabal H, Alalawi AS, Al-Nooh N. The impact of bariatric surgery on type 2 diabetes mellitus remission: a systematic review. Cureus. 2024;16:e74755.
160. Laferrère B, Pattou F. Weight-independent mechanisms of glucose control after Roux-en-Y gastric bypass. Front Endocrinol. 2018;9:530.
161. Cottam A, Cottam D, Roslin M, Surve A. Exploring bariatric surgery’s impact on weight loss and diabetes: sodium and glucose receptor modulation. JSLS. 2024;28:e2023.00051.
162. Cavin J, Bado A, Le Gall M. Intestinal adaptations after bariatric surgery: consequences on glucose homeostasis. Trends Endocrinol Metab. 2017;28:354-64.
163. Turk E, Zabel B, Mundlos S, Dyer J, Wright EM. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature. 1991;350:354-6.
164. Wright EM, Turk E, Zabel B, Mundlos S, Dyer J. Molecular genetics of intestinal glucose transport. J Clin Investig. 1991;88:1435-40.
165. Muralidharan H, Sajith A, Elsayed N, Syed Iqbaluddin J, Gupta P, Ahmed Babiker Rahamtalla D. A rare case of congenital glucose galactose malabsorption due to SLC5A1 Mutation. Cureus. 2025;17:e98692.
166. Chan AP, Namjoshi SS, Jardack PM, et al. Long-term dietary changes in subjects with glucose galactose malabsorption secondary to biallelic mutations of SLC5A1. Dig Dis Sci. 2021;66:4414-22.
167. Vallon V. Glucose transporters in the kidney in health and disease. Pflugers Arch - Eur J Physiol. 2020;472:1345-70.
168. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol. 2011;22:104-12.
170. Vallon V, Gerasimova M, Rose MA, et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014;306:F194-204.
171. Vallon V, Thomson SC. Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu Rev Physiol. 2012;74:351-75.
172. Song P, Huang W, Onishi A, et al. Knockout of Na+-glucose cotransporter SGLT1 mitigates diabetes-induced upregulation of nitric oxide synthase NOS1 in the macula densa and glomerular hyperfiltration. Am J Physiol Renal Physiol. 2019;317:F207-17.
173. Bankir L, Crambert G, Vargas-Poussou R. The SLC6A18 transporter is most likely a Na-dependent glycine/urea antiporter responsible for urea secretion in the proximal straight tubule: influence of this urea secretion on glomerular filtration rate. Nephron. 2024:1-27.
174. Nespoux J, Patel R, Hudkins KL, et al. Gene deletion of the Na+-glucose cotransporter SGLT1 ameliorates kidney recovery in a murine model of acute kidney injury induced by ischemia-reperfusion. Am J Physiol Renal Physiol. 2019;316:F1201-10.
175. Sasaki M, Sasako T, Kubota N, et al. Dual regulation of gluconeogenesis by insulin and glucose in the proximal tubules of the kidney. Diabetes. 2017;66:2339-50.
176. Madunić IV, Breljak D, Karaica D, Koepsell H, Sabolić I. Expression profiling and immunolocalization of Na+-d-glucose-cotransporter 1 in mice employing knockout mice as specificity control indicate novel locations and differences between mice and rats. Pflugers Arch - Eur J Physiol. 2017;469:1545-65.
177. Du J, Gu J, Deng J, et al. The expression and survival significance of sodium glucose transporters in pancreatic cancer. BMC Cancer. 2022;22:116.
178. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21:512-7.
179. Solini A, Sebastiani G, Nigi L, Santini E, Rossi C, Dotta F. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes Metab. 2017;43:512-20.
180. Kuhre RE, Ghiasi SM, Adriaenssens AE, et al. No direct effect of SGLT2 activity on glucagon secretion. Diabetologia. 2019;62:1011-23.
181. Suga T, Kikuchi O, Kobayashi M, et al. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels. Mol Metab. 2019;19:1-12.
182. Mühlemann M, Zdzieblo D, Friedrich A, et al. Altered pancreatic islet morphology and function in SGLT1 knockout mice on a glucose-deficient, fat-enriched diet. Mol Metab. 2018;13:67-76.
183. Saponaro C, Mühlemann M, Acosta-Montalvo A, et al. Interindividual heterogeneity of SGLT2 expression and function in human pancreatic islets. Diabetes. 2020;69:902-14.
184. Chiba Y, Sugiyama Y, Nishi N, Nonaka W, Murakami R, Ueno M. Sodium/glucose cotransporter 2 is expressed in choroid plexus epithelial cells and ependymal cells in human and mouse brains. Neuropathology. 2020;40:482-91.
185. O’Malley D, Reimann F, Simpson AK, Gribble FM. Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing. Diabetes. 2006;55:3381-6.
186. Zhu Y, Verkhratsky A, Chen H, Yi C. Understanding glucose metabolism and insulin action at the blood–brain barrier: implications for brain health and neurodegenerative diseases. Acta Physiol. 2025;241:e14283.
187. Ferrannini E. Sodium-glucose Co-transporters and their inhibition: clinical physiology. Cell Metab. 2017;26:27-38.
188. Zhang Z, Li Y, Gu HF, Li N. Pharmacological mechanisms and clinical applications between SGLT1 and SGLT2 inhibitors in type 2 diabetes and diabetic kidney disease: an analytic review. Biomed Pharmacother. 2025;193:118837.
189. Van Lerberghe R, Mahieu E, Vanuytsel J, Vanhaute K, Vanfraechem C, Claeys L. Familial renal glucosuria presenting as paroxysmal glucosuria and hypercalciuria due to a novel SLC5A2 heterozygous variant. Eur J Case Rep Intern Med. 2023;10.
190. Diederich J, Mounkoro P, Tirado HA, Chevalier N, Van Schaftingen E, Veiga-da-Cunha M. SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia. Cell Mol Life Sci. 2023;80:259.
191. Hanke J, Romejko K, Niemczyk S. Sodium-glucose cotransporter-2 inhibitors in diabetes and beyond: mechanisms, pleiotropic benefits, and clinical use - reviewing protective effects exceeding glycemic control. Molecules. 2025;30:4125.
192. Hummel CS, Lu C, Loo DDF, Hirayama BA, Voss AA, Wright EM. Glucose transport by human renal Na+/d-glucose cotransporters SGLT1 and SGLT2. Am J Physiol Cell Physiol. 2011;300:C14-21.
193. Miyata KN, Lo C, Zhao S, et al. Angiotensin II up-regulates sodium-glucose co-transporter 2 expression and SGLT2 inhibitor attenuates Ang II-induced hypertensive renal injury in mice. Clin Sci. 2021;135:943-61.
194. Pontoglio M, Prié D, Cheret C, et al. HNF1α controls renal glucose reabsorption in mouse and man. EMBO Rep. 2000;1:359-65.
195. Norton CE, Fourcaudot M, Hu C, et al. Sodium-glucose co-transporter (SGLT) and glucose transporter (GLUT) expression in the kidney of type 2 diabetic subjects. Diabetes Obes Metab. 2017;19:1322-26.
196. Gajjar A, Raju AK, Gajjar A, et al. SGLT2 inhibitors and GLP-1 receptor agonists in cardiovascular-kidney-metabolic syndrome. Biomedicines. 2025;13:1924.
197. Salvatore T, Galiero R, Caturano A, et al. An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors. Int J Mol Sci. 2022;23:3651.
198. Chen J, Williams S, Ho S, et al. Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members. Diab Ther. 2010;1:57-92.
199. Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91:733-94.
200. Blanco AM, Bertucci JI, Ramesh N, Delgado MJ, Valenciano AI, Unniappan S. Ghrelin facilitates GLUT2-, SGLT1- and SGLT2-mediated intestinal glucose transport in goldfish (Carassius auratus). Sci Rep. 2017;7:45024.
201. Bolla AM, Butera E, Pellegrini S, et al. Expression of glucose transporters in duodenal mucosa of patients with type 1 diabetes. Acta Diabetol. 2020;57:1367-73.
202. Hu Z, Liao Y, Wang J, Wen X, Shu L. Potential impacts of diabetes mellitus and anti-diabetes agents on expressions of sodium-glucose transporters (SGLTs) in mice. Endocrine. 2021;74:571-81.
203. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharmacokinet. 2005;20:452-77.
204. Chae H, Augustin R, Gatineau E, et al. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans. Mol Metab. 2020;42:101071.
205. Vergari E, Knudsen JG, Ramracheya R, et al. Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion. Nat Commun. 2019;10:139.
206. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Investig. 2014;124:499-508.
207. Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Investig. 2014;124:509-14.
208. Scafoglio C, Hirayama BA, Kepe V, et al. Functional expression of sodium-glucose transporters in cancer. Proc. Natl. Acad. Sci. U.S.A. 2015;112.
209. Nakhaei A, Delavar K, Azim AS, et al. SGLT-2 inhibitors beyond diabetes: a new frontier in cancer treatment. Diabetes Res Clin Pract. 2025;229:112925.
210. Dong M, Chen H, Wen S, et al. The neuronal and non-neuronal pathways of sodium-glucose cotransporter-2 inhibitor on body weight-loss and insulin resistance. Diabetes Metab Syndr Obes. 2023;16:425-35.
211. Pawlos A, Broncel M, Woźniak E, Gorzelak-Pabiś P. Neuroprotective effect of SGLT2 inhibitors. Molecules. 2021;26:7213.
212. Nguyen T, Wen S, Gong M, et al. Dapagliflozin activates neurons in the central nervous system and regulates cardiovascular activity by inhibiting SGLT-2 in mice. Diabetes Metab Syndr Obes. 2020;13:2781-99.
213. Subramaniam M, Loewen ME. Review: a species comparison of the kinetic homogeneous and heterogeneous organization of sodium-dependent glucose transport systems along the intestine. Comp Biochem Phys A. 2023;285:111492.
214. Tabatabai NM, Blumenthal SS, Lewand DL, Petering DH. Mouse kidney expresses mRNA of four highly related sodium-glucose cotransporters: regulation by cadmium. Kidney Int. 2003;64:1320-30.
215. Aljure O, Díez-Sampedro A. Functional characterization of mouse sodium/glucose transporter type 3b. Am J Physiol Cell Physiol. 2010;299:C58-65.
216. Sala-Rabanal M, Hirayama BA, Loo DDF, Chaptal V, Abramson J, Wright EM. Bridging the gap between structure and kinetics of human SGLT1. Am J Physiol Cell Physiol. 2012;302:C1293-305.
217. Han L, Qu Q, Aydin D, et al. Structure and mechanism of the SGLT family of glucose transporters. Nature. 2021;601:274-9.
218. Barcelona S, Menegaz D, Díez-Sampedro A. Mouse SGLT3a generates proton-activated currents but does not transport sugar. Am J Physiol Cell Physiol. 2012;302:C1073-82.
219. Díez-Sampedro A, Hirayama BA, Osswald C, et al. A glucose sensor hiding in a family of transporters. Proc. Natl. Acad. Sci. U.S.A. 2003;100:11753-8.
220. Soták M, Casselbrant A, Rath E, et al. Intestinal sodium/glucose cotransporter 3 expression is epithelial and downregulated in obesity. Life Sci. 2021;267:118974.
221. Gribble FM, Williams L, Simpson AK, Reimann F. A Novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Diabetes. 2003;52:1147-54.
222. Delaere F, Duchampt A, Mounien L, et al. The role of sodium-coupled glucose co-transporter 3 in the satiety effect of portal glucose sensing. Mol Metab. 2013;2:47-53.
223. Pal A, Rhoads DB, Tavakkoli A. Foregut exclusion disrupts intestinal glucose sensing and alters portal nutrient and hormonal milieu. Diabetes. 2015;64:1941-50.
224. Lee EY, Kaneko S, Jutabha P, et al. Distinct action of the α-glucosidase inhibitor miglitol on SGLT3, enteroendocrine cells, and GLP1 secretion. J Endocrinol. 2015;224:205-14.
225. Mithieux G, Misery P, Magnan C, et al. Portal sensing of intestinal gluconeogenesis is a mechanistic link in the diminution of food intake induced by diet protein. Cell Metab. 2005;2:321-9.
226. Yamazaki Y, Harada S, Tokuyama S. Sodium-glucose transporter type 3-mediated neuroprotective effect of acetylcholine suppresses the development of cerebral ischemic neuronal damage. Neuroscience. 2014;269:134-42.
227. Tazawa S, Yamato T, Fujikura H, et al. SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci. 2005;76:1039-50.
228. Yamanouchi T, Minoda S, Yabuuchi M, et al. Plasma 1,5-anhydro-D-glucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes. 1989;38:723-9.
229. Akanuma Y, Morita M, Fukuzawa N, Yamanouchi T, Akanuma H. Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients. Diabetologia. 1988;31:BF00277486.
230. Sun J, Dou JT, Wang XL, et al. Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. Chin Med J (Engl). 2011;124:3641-5.
231. Yamanouchi T, Shinohara T, Ogata N, Tachibana Y, Akaoka I, Miyashita H. Common reabsorption system of 1,5-anhydro-d-glucitol, fructose, and mannose in rat renal tubule. BBA-Gen Subjects. 1996;1291:89-95.
232. Veiga-da-Cunha M, Chevalier N, Stephenne X, et al. Failure to eliminate a phosphorylated glucose analog leads to neutropenia in patients with G6PT and G6PC3 deficiency. Proc. Natl. Acad. Sci. U.S.A. 2019;116:1241-50.
233. Wortmann SB, Van Hove JLK, Derks TGJ, et al. Treating neutropenia and neutrophil dysfunction in glycogen storage disease type Ib with an SGLT2 inhibitor. Blood. 2020;136:1033-43.
234. Forester BR, Zhang R, Schuhler B, Brostek A, Gonzalez-Vicente A, Garvin JL. Knocking out sodium glucose-linked transporter 5 prevents fructose-induced renal oxidative stress and salt-sensitive hypertension. Hypertension. 2024;81:1296-307.
235. Grempler R, Augustin R, Froehner S, et al. Functional characterisation of human SGLT-5 as a novel kidney-specific sodium-dependent sugar transporter. FEBS Lett. 2011;586:248-53.
236. Fukuzawa T, Fukazawa M, Ueda O, et al. SGLT5 reabsorbs fructose in the kidney but its deficiency paradoxically exacerbates hepatic steatosis induced by fructose. PLoS ONE. 2013;8:e56681.
237. Li M, Maruthur NM, Loomis SJ, et al. Genome-wide association study of 1,5-anhydroglucitol identifies novel genetic loci linked to glucose metabolism. Sci Rep. 2017;7:2812.
238. Loomis SJ, Köttgen A, Li M, et al. Rare variants in SLC5A10 are associated with serum 1,5-anhydroglucitol (1,5-AG) in the atherosclerosis risk in communities (ARIC) study. Sci Rep. 2019;9:5941.
239. Long T, Hicks M, Yu H, et al. Whole-genome sequencing identifies common-to-rare variants associated with human blood metabolites. Nat Genet. 2017;49:568-78.
240. Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the g-protein-coupled receptor FFAR2. Diabetes. 2012;61:364-71.
241. Powell DR, Smith M, Greer J, et al. LX4211 Increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther. 2013;345:250-9.
242. Jyoti, Dey P. Mechanisms and implications of the gut microbial modulation of intestinal metabolic processes. npj Metab Health Dis. 2025;3:24.
243. Li Z, Freiberg S, Music ML, et al. Cardiac sodium-glucose co-transporter 1 (SGLT1) contributes to heart failure in a mouse model of diabetic cardiomyopathy. Basic Res Cardiol. 2025;120:1193-207.
244. Zhao M, Li N, Zhou H. SGLT1: a potential drug target for cardiovascular disease. Drug Des Devel Ther. 2023;17:2011-23.
245. Yamazaki Y, Harada S, Wada T, Hagiwara T, Yoshida S, Tokuyama S. Sodium influx through cerebral sodium-glucose transporter type 1 exacerbates the development of cerebral ischemic neuronal damage. Eur J Pharmacol. 2017;799:103-10.
246. Sano R, Shinozaki Y, Ohta T. Sodium-glucose cotransporters: Functional properties and pharmaceutical potential. J Diabetes Invest. 2020;11:770-82.
247. Shibazaki T, Tomae M, Ishikawa-Takemura Y, et al. KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2012;342:288-96.
248. Parveen A, Parveen S, Vats N, et al. An insight into commercially available SGLT2 inhibitors and their structure-activity relationship studies. Arch Pharm (Weinheim). 2025;358:e70127.
249. Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020;295:14379-90.
250. Čertíková Chábová V, Zakiyanov O. Sodium glucose cotransporter-2 inhibitors: spotlight on favorable effects on clinical outcomes beyond diabetes. Int J Mol Sci. 2022;23:2812.
251. Gieroba B, Kryska A, Sroka-Bartnicka A. Type 2 diabetes mellitus - conventional therapies and future perspectives in innovative treatment. Biochem Biophys Rep. 2025;42:102037.
252. Shyr ZA, Yan Z, Ustione A, Egan EM, Remedi MS. SGLT2 inhibitors therapy protects glucotoxicity-induced β-cell failure in a mouse model of human KATP-induced diabetes through mitigation of oxidative and ER stress. PLoS ONE. 2022;17:e0258054.
253. Bechmann LE, Emanuelsson F, Nordestgaard BG, Benn M. SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type. Atherosclerosis. 2024;394:117236.
254. Pedersen MG, Ahlstedt I, El Hachmane MF, Göpel SO. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells. Sci Rep. 2016;6:31214.
255. Saponaro C, Gmyr V, Thévenet J, et al. The GLP1R agonist liraglutide reduces hyperglucagonemia induced by the SGLT2 inhibitor dapagliflozin via somatostatin release. Cell Rep. 2019;28:1447-1454.e4.
257. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endo. 2013;1:208-19.
258. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021:m4573.
259. Bolinder J, Ljunggren Ö, Johansson L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2013;16:159-69.
260. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323-34.
261. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-57.
262. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-57.
263. Lambers Heerspink HJ, De Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853-62.
264. Kawasoe S, Maruguchi Y, Kajiya S, et al. Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes. BMC Pharmacol Toxicol. 2017;18:23.
265. Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart failure: an underappreciated complication of diabetes. a consensus report of the American diabetes association. Diabetes Care. 2022;45:1670-90.
266. Seferović PM, Coats AJ, Ponikowski P, et al. European society of cardiology/heart failure association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. Eur J Heart Fail. 2020;22:196-213.
267. Zhu Y, Lv C, Yang H, et al. Chronic cardiorenal syndrome: cardio-renal protective effect of SGLT2i. Renal Fail. 2025;47:2575921.
268. Haider SH, Irfan A, Sheikh SM, Larik MO, Raza A, Khabir Y. Evaluating the safety and efficacy of SGLT-2 Inhibitors on reducing cardiovascular and renal mortality, morbidity and inflammatory outcomes in various patient populations: a systematic review and meta-analysis of 92 920 patients. Clin Med Insights Cardiol. 2025;19:11795468251347777.
269. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413-24.
270. Perkovic V, De Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endo. 2018;6:691-704.
271. Rieg T, Masuda T, Gerasimova M, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol Renal Physiol. 2014;306:F188-93.
272. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther. 2009;85:520-6.
273. Liu J, Lee T, Defronzo RA. Why Do SGLT2 Inhibitors Inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes. 2012;61:2199-204.
274. Suki M, Imam A, Amer J, et al. SGLT2 inhibitors in MASLD (metabolic dysfunction-associated steatotic liver disease) associated with sustained hepatic benefits, besides the cardiometabolic. Pharmaceuticals. 2025;18:1118.
275. Tanriover C, Ucku D, Akyol M, et al. Potential use of SGLT-2 inhibitors in obstructive sleep apnea: a new treatment on the horizon. Sleep Breath. 2022;27:77-89.
276. Maffei P, Bettini S, Busetto L, Dassie F. SGLT2 inhibitors in the management of type 1 diabetes (T1D): an update on current evidence and recommendations. Diabetes Metab Syndr Obes. 2023;16:3579-98.
278. Cefalu WT, Leiter LA, Yoon K, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. The Lancet. 2013;382:941-50.
279. Baek H, Jeong C, Yang Y, et al. Diabetic ketoacidosis as an effect of sodium-glucose cotransporter 2 inhibitor: real world insights. Diabetes Metab J. 2024;48:1169-75.
280. European Medicines Agency. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. 2016. https://www.ema.europa.eu/en/news/ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes.
281. Koceva A, Kravos Tramšek NA. From sweet to sour: SGLT-2-inhibitor-induced euglycemic diabetic ketoacidosis. JPM. 2024;14:665.
282. Li L, Andrews EB, Li X, et al. Incidence of diabetic ketoacidosis and its trends in patients with type 1 diabetes mellitus identified using a U.S. claims database, 2007-2019. J Diabetes Complicat. 2021;35:107932.
283. Del Prato S, Nauck M, Durán-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab. 2015;17:581-90.
284. Fadini GP, Longato E, Morieri ML, et al. Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk. Lancet Reg Health Eur. 2024;38:100847.
285. Danne T, Biester T, Kordonouri O. Combined SGLT1 and SGLT2 inhibitors and their role in diabetes care. Diabetes Technol Ther. 2018;20.
286. Cefalo CMA, Cinti F, Moffa S, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019;18:20.
287. Polidori D, Sha S, Mudaliar S, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion. Diabetes Care. 2013;36:2154-61.
288. Chen L, Hou B, Lalonde S, et al. Sugar transporters for intercellular exchange and nutrition of pathogens. Nature. 2010;468:527-32.
289. Szablewski L. Human glucose transporters in health and selected neurodegenerative diseases. Int J Mol Sci. 2025;26:7392.
290. Hu B, Wu H, Huang W, Song J, Zhou Y, Lin Y. SWEET gene family in Medicago truncatula: genome-wide identification, expression and substrate specificity analysis. Plants. 2019;8:338.
291. Santer R, Hillebrand G, Steinmann B, Schaub J. Intestinal glucose transport: evidence for a membrane traffic-based pathway in humans. Gastroenterology. 2003;124:34-9.
292. Liu H, Huang D, Mcarthur DL, Boros LG, Nissen N, Heaney AP. Fructose induces transketolase flux to promote pancreatic cancer growth. Cancer Res. 2010;70:6368-76.
293. Włodarczyk J, Włodarczyk M, Zielińska M, Jędrzejczak B, Dziki Ł, Fichna J. Blockade of fructose transporter protein GLUT5 inhibits proliferation of colon cancer cells: proof of concept for a new class of anti-tumor therapeutics. Pharmacol Rep. 2021;73:939-45.
294. Ruan Z, Wang Y, Shi L, Yang X. Progress of research on glucose transporter proteins in hepatocellular carcinoma. World J Hepatol. 2025;17:104715.
295. Sędzikowska A, Szablewski L. Human glucose transporters in renal glucose homeostasis. Int J Mol Sci. 2021;22:13522.
296. Falsetti L, Tarquinio N, Mucci L, et al. Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors. Eur J Clin Pharmacol. 2026;82:93.
297. Kittipibul V, Cox ZL, Chesdachai S, Fiuzat M, Lindenfeld J, Mentz RJ. Genitourinary tract infections in patients taking SGLT2 inhibitors. J Am Coll Cardiol. 2024;83:1568-78.
298. Mederle AL, Dumitrescu P, Borza C, Kundnani NR. Cutaneous adverse drug reactions associated with SGLT2 inhibitors. JCM. 2024;14:188.
299. Morace C, Lorello G, Bellone F, et al. Ketoacidosis and SGLT2 inhibitors: a narrative review. Metabolites. 2024;14:264.
300. Yin J, You N, Li F, Lu M, Zeng S, Zhu F. State-of-the-art application of artificial intelligence to transporter-centered functional and pharmaceutical research. Curr Drug Metab. 2023;24:162-74.
301. Tu G, Fu T, Zheng G, et al. Computational chemistry in structure-based solute carrier transporter drug design: recent advances and future perspectives. J Chem Inf Model. 2024;64:1433-55.
302. Menon AV, Song B, Chao L, et al. Unraveling the future of genomics: CRISPR, single-cell omics, and the applications in cancer and immunology. Front Genome Ed. 2025;7:1565387.
303. Yiu T, Chen B, Wang H, Feng G, Fu Q, Hu H. Transformative advances in single-cell omics: a comprehensive review of foundation models, multimodal integration and computational ecosystems. J Transl Med. 2025;23:1176.
304. Ren Z, Zhao J, Li S, Yuan H. Targeting glucose transporter 1 (GLUT1) in cancer: molecular mechanisms and nanomedicine applications. Int J Nanomedicine. 2025;20:11859-79.
305. Zhou Y, Liang F, Tian H, Luo D, Wang Y, Yang S. Mechanisms of gut microbiota-immune-host interaction on glucose regulation in type 2 diabetes. Front Microbiol. 2023;14:1121695.
306. Carruthers A, DeZutter J, Ganguly A, Devaskar SU. Will the original glucose transporter isoform please stand up! Am J Physiol Endocrinol Metab. 2009;297:E836-48.
307. Luo H, Wei J, Wu S, Zheng Q, Lin X, Chen P. Elucidating the role of the GC/GR/GLUT1 axis in steroid-induced osteonecrosis of the femoral head: a proteomic approach. Bone. 2024;183:117074.
308. U.S. Food and Drug Administration. INVOKANA (canagliflozin) prescribing information. Available from:https://www.accessdata.fda.gov/scripts/cder/daf/[Last accessed on 23 October 2026].
309. European Medicines Agency. Invokana (canagliflozin): EPAR. Available from:https://www.ema.europa.eu/en/medicines/human/EPAR/invokana[Last accessed on 23 October 2026].
310. U.S. Food and Drug Administration. FARXIGA (dapagliflozin) prescribing information. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/[Last accessed on 23 October 2026].
311. European Medicines Agency. Forxiga (dapagliflozin): EPAR. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/forxiga[Last accessed on 23 October 2026].
312. U.S. Food and Drug Administration. JARDIANCE (empagliflozin) prescribing information. Available from: www.accessdata.fda.gov/scripts/cder/daf/[Last accessed on 23 October 2026].
313. European Medicines Agency. Jardiance (empagliflozin): EPAR. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance[Last accessed on 23 October 2026].
314. U.S. Food and Drug Administration. STEGLATRO (ertugliflozin) prescribing information. Available from: www.accessdata.fda.gov/scripts/cder/daf/[Last accessed on 23 October 2026].
315. European Medicines Agency. Steglatro (ertugliflozin): EPAR. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/steglatro[Last accessed on 23 October 2026].
316. U.S. Food and Drug Administration. INPEFA (sotagliflozin) prescribing information. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/[Last accessed on 23 October 2026].
317. European Medicines Agency. Zynquista (sotagliflozin): EPAR (withdrawn). Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zynquista [Last accessed on 23 October 2026].
